Monitor upcoming IND submission and initiation of the XRX-OXY-102 clinical study. Key catalyst is data from the two-part bridging study—positive results could support a 505(b)(2) NDA filing. No near-term revenue catalysts; stock likely to trade on regulatory milestones and financing news.
Price Chart
Executive Summary
XORTX Therapeutics filed a 6-K announcing the appointment of Mika Grasso as Co-CEO and providing a corporate update on its gout program (XRx-026). The company is preparing an IND submission following FDA guidance and targeting a $700 million per year market. This is primarily an operational/corporate update with no new financial data or definitive clinical results—a routine regulatory milestone update for a micro-cap biotech.
Key Facts
- Announced appointment of Mika Grasso as Co-CEO, responsible for finance and public markets.
- FDA Type B meeting clarified key steps required for NDA submission via 505(b)(2) pathway for gout program XRx-026.
- Company is developing an IND including new pharmacology, toxicology, chemistry, and manufacturing data.
- Planned two-part clinical study (XRX-OXY-102) to characterize XORLO pharmacokinetics and establish therapeutic equivalence to allopurinol.
- Target addressable market for XRx-026 is $700 million per year (inflation-adjusted Febuxostat peak sales).
- Company aims to advance gout program toward marketing approval within the next 18 months.
- No financial figures (revenue, earnings, cash position, deal value) were disclosed in the filing.
Financial Impact
No financial figures provided. The press release references a $700 million annual market opportunity for the gout program, but this is a market estimate, not company financials.
Risk Factors
- Company is pre-revenue; execution risk on IND preparation and clinical study initiation.
- Need for additional capital to fund development programs and operations (stated in risk factors).
- Lengthy regulatory pathway; FDA could require additional studies beyond the proposed bridging study.
- No disclosed cash runway or financing details in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-004112 |
| Document: f6k_061526.htm | 0001171843-26-004112 |
| Document: 0001171843-26-004112-index-headers.html | 0001171843-26-004112 |
| Document: 0001171843-26-004112-index.html | 0001171843-26-004112 |
| Document: 0001171843-26-004112.txt | 0001171843-26-004112 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 17d ago | 6-K | $1.41 | awaiting T+20 | — | $1.07 (−24.11%) |
Sep 18, 2026 5w ago | 6-K | $1.92 $1.24 | ▼ −35.42% | ▼ −35.62% | $1.07 (−44.27%) |
Sep 18, 2026 5w ago | Press Release | $1.92 $1.24 | ▼ −35.42% | ▼ −35.62% | $1.07 (−44.27%) |
Sep 4, 2026 7w ago | 6-K | $2.31 $1.70 | ▲ +26.41% | ▲ +27.01% | $1.07 (+53.68%) |
Aug 28, 2026 8w ago | 6-K | $2.34 $1.71 | ▼ −26.86% | ▼ −27.12% | $1.07 (−54.23%) |
Aug 3, 2026 11w ago | 6-K | $2.16 $2.16 | · 0.00% | ▲ +1.24% | $1.07 (−50.46%) |
Jul 29, 2026 12w ago | 6-K | $2.06 $2.22 | ▲ +7.67% | ▲ +2.65% | $1.07 (−48.06%) |
Jun 15, 2026 19w ago | 6-K | $2.19 $2.03 | ▼ −7.31% | ▼ −6.56% | $1.07 (−51.14%) |
Jun 12, 2026 19w ago | 6-K | $2.19 $2.03 | ▼ −7.31% | ▼ −6.56% | $1.07 (−51.14%) |
May 19, 2026 22w ago | 6-K / PRESS-RELEASE | $2.32 $2.15 | ▲ +7.33% | ▲ +8.31% | $1.07 (+53.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers